JP2024517477A5 - - Google Patents

Info

Publication number
JP2024517477A5
JP2024517477A5 JP2023569861A JP2023569861A JP2024517477A5 JP 2024517477 A5 JP2024517477 A5 JP 2024517477A5 JP 2023569861 A JP2023569861 A JP 2023569861A JP 2023569861 A JP2023569861 A JP 2023569861A JP 2024517477 A5 JP2024517477 A5 JP 2024517477A5
Authority
JP
Japan
Prior art keywords
melanoma
composition
patient
use according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028456 external-priority patent/WO2022240799A1/en
Publication of JP2024517477A publication Critical patent/JP2024517477A/ja
Publication of JP2024517477A5 publication Critical patent/JP2024517477A5/ja
Pending legal-status Critical Current

Links

JP2023569861A 2021-05-12 2022-05-10 黒色腫を治療するためのリプレチニブ Pending JP2024517477A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163187903P 2021-05-12 2021-05-12
US63/187,903 2021-05-12
US202163231384P 2021-08-10 2021-08-10
US63/231,384 2021-08-10
US202263313570P 2022-02-24 2022-02-24
US63/313,570 2022-02-24
PCT/US2022/028456 WO2022240799A1 (en) 2021-05-12 2022-05-10 Ripretinib for treating melanoma

Publications (2)

Publication Number Publication Date
JP2024517477A JP2024517477A (ja) 2024-04-22
JP2024517477A5 true JP2024517477A5 (https=) 2025-05-20

Family

ID=81854549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569861A Pending JP2024517477A (ja) 2021-05-12 2022-05-10 黒色腫を治療するためのリプレチニブ

Country Status (6)

Country Link
US (1) US20240122906A1 (https=)
EP (1) EP4337201A1 (https=)
JP (1) JP2024517477A (https=)
AU (1) AU2022273288A1 (https=)
CA (1) CA3218436A1 (https=)
WO (1) WO2022240799A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118416236A (zh) * 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
TWI878335B (zh) * 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法

Similar Documents

Publication Publication Date Title
JP2022544234A5 (https=)
JP2021113201A5 (https=)
JP2024514202A (ja) Ｅｒｋ１／２の複素環式阻害剤の使用
TW202122082A (zh) 治療胃腸道基質瘤方法
JP2025503385A5 (https=)
US20240423978A1 (en) EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER
US20240122921A1 (en) Methods for cancer therapy
EP4110326A1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP2022526159A5 (https=)
JP2022502492A5 (https=)
US6613768B1 (en) Treatment of female arousal disorder
EP4093394A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2024517477A5 (https=)
JPWO2005009444A1 (ja) 医薬組成物
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
WO2019220375A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
WO2022234409A1 (en) Compounds and compositions for the treatment of mpnst
WO2021094379A1 (en) Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
Zachariah et al. Antihypertensive effects of a new sustained‐release formulation of nifedipine
JP6691971B2 (ja) 慢性骨髄性白血病を治療又は寛解するための医薬組成物
CA3255389A1 (en) Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer
TW202304457A (zh) 配製物
JP2025540124A (ja) 乳がんを治療する方法
HK40030002B (zh) 癌症疗法